UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 80

Sortiert nach

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

Journal of Virology, 2008-11, Vol.82 (21), p.10366-10374

2008

Link zum Volltext

Verfügbarkeit prüfen

Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic Barrier

Journal of Virology, 2007-12, Vol.81 (24), p.13845-13851

2007

Link zum Volltext

Verfügbarkeit prüfen

A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional Nanobodies

Archives of biochemistry and biophysics, 2012-10, Vol.526 (2), p.114-123

2012

Link zum Volltext

Verfügbarkeit prüfen

Indolopyridones Inhibit Human Immunodeficiency Virus Reverse Transcriptase with a Novel Mechanism of Action

Journal of Virology, 2006-12, Vol.80 (24), p.12283-12292

2006

Link zum Volltext

Verfügbarkeit prüfen

Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy

Journal of Virology, 2001-06, Vol.75 (11), p.4999-5008

2001

Link zum Volltext

Verfügbarkeit prüfen

A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs

Antimicrobial Agents and Chemotherapy, 1998-02, Vol.42 (2), p.269-276

1998

Link zum Volltext

Verfügbarkeit prüfen

Short-Cycle Structured Intermittent Treatment of Chronic HIV Infection with Highly Active Antiretroviral Therapy: Effects on Virologic, Immunologic, and Toxicity Parameters

Proceedings of the National Academy of Sciences - PNAS, 2001-12, Vol.98 (26), p.15161-15166

2001

Link zum Volltext

Verfügbarkeit prüfen

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples

AIDS (London), 2000-09, Vol.14 (13), p.1943-1948

2000

Link zum Volltext

Verfügbarkeit prüfen

A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance

Antimicrobial Agents and Chemotherapy, 1999-08, Vol.43 (8), p.1961-1967

1999

Link zum Volltext

Verfügbarkeit prüfen

A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V

Antimicrobial Agents and Chemotherapy, 2000-03, Vol.44 (3), p.568-573

2000

Link zum Volltext

Verfügbarkeit prüfen

Development of robust antiviral assays for profiling compounds against a panel of positive-strand RNA viruses using ATP/luminescence readout

Journal of virological methods, 2008-07, Vol.151 (1), p.121-125

2008

Link zum Volltext

Verfügbarkeit prüfen

Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance

Current medical research and opinion, 2006-12, Vol.22 (12), p.2603-2612

2006

Link zum Volltext

Verfügbarkeit prüfen

Correlation between Viral Resistance to Zidovudine and Resistance at the Reverse Transcriptase Level for a Panel of Human Immunodeficiency Virus Type 1 Mutants

Journal of Virology, 2001-08, Vol.75 (15), p.7202-7205

2001

Link zum Volltext

Verfügbarkeit prüfen

Interference between D30N and L90M in Selection and Development of Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1

Antimicrobial Agents and Chemotherapy, 2002-03, Vol.46 (3), p.708-715

2002

Link zum Volltext

Verfügbarkeit prüfen

Correlation of Phenotypic Zidovudine Resistance with Mutational Patterns in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1: Interpretation of Established Mutations and Characterization of New Polymorphisms at Codons 208, 211, and 214

Antimicrobial Agents and Chemotherapy, 2003-01, Vol.47 (1), p.54-61

2003

Link zum Volltext

Verfügbarkeit prüfen

Comparative Analysis of Two Commercial Phenotypic Assays for Drug Susceptibility Testing of Human Immunodeficiency Virus Type 1

Journal of Clinical Microbiology, 2002-01, Vol.40 (1), p.31-35

2002

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of Protease and Reverse Transcriptase Drug Resistance Mutations over Time in Drug-Naïve Human Immunodeficiency Virus Type 1-Positive Individuals in Rio de Janeiro, Brazil

Antimicrobial Agents and Chemotherapy, 2002-09, Vol.46 (9), p.3075-3079

2002

Link zum Volltext

Verfügbarkeit prüfen

High Degree of Interlaboratory Reproducibility of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Sequencing of Plasma Samples from Heavily Treated Patients

Journal of Clinical Microbiology, 2001-04, Vol.39 (4), p.1522-1529

2001

Link zum Volltext

Verfügbarkeit prüfen

ANTIVIRAL ACTIVITY OF TENOFOVIR (PMPA) AGAINST NUCLEOSIDE-RESISTANT CLINICAL HIV SAMPLES

Nucleosides, nucleotides & nucleic acids, 2001-04, Vol.20 (4-7), p.1025-1028

2001

Link zum Volltext

Verfügbarkeit prüfen

Testing Genotypic and Phenotypic Resistance in Human Immunodeficiency Virus Type 1 Isolates of Clade B and Other Clades from Children Failing Antiretroviral Therapy

Journal of Clinical Microbiology, 2002-12, Vol.40 (12), p.4512-4519

2002

Link zum Volltext

Verfügbarkeit prüfen

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles

Virology (New York, N.Y.), 2010-07, Vol.402 (2), p.338-346

2010

Link zum Volltext

Verfügbarkeit prüfen

Patterns of Resistance and Cross-Resistance to Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors in Patients Treated with the Nonnucleoside Reverse Transcriptase Inhibitor Loviride

Antimicrobial Agents and Chemotherapy, 1998-12, Vol.42 (12), p.3123-3129

1998

Link zum Volltext

Verfügbarkeit prüfen

Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains

European journal of medicinal chemistry, 2007-05, Vol.42 (5), p.567-579

2007

Link zum Volltext

Verfügbarkeit prüfen

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

AIDS (London), 2000-12, Vol.14 (18), p.2857-2867

2000

Link zum Volltext

Verfügbarkeit prüfen

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor

Antiviral research, 2011-08, Vol.91 (2), p.167-176

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 80

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(74)

Publikationsform

Artikel
(80)

Sprache

Englisch
(80)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(67)
Life Sciences & Biomedicine
(66)
Humans
(64)
Biological And Medical Sciences
(57)
Hiv-1 - Drug Effects
(51)
Medical Sciences
(49)
Virology
(43)
Hiv-1 - Genetics
(41)
Infectious Diseases
(39)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(38)
Hiv Infections - Drug Therapy
(38)
Pharmacology. Drug Treatments
(38)
Hiv Infections - Virology
(37)
Antiviral Agents
(36)
Microbiology
(36)
Mutation
(33)
Aids/hiv
(31)
Immunology
(30)
Phenotype
(30)
Anti-Hiv Agents - Pharmacology
(28)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic Barrier

A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional Nanobodies

Indolopyridones Inhibit Human Immunodeficiency Virus Reverse Transcriptase with a Novel Mechanism of Action

Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy

A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs

Short-Cycle Structured Intermittent Treatment of Chronic HIV Infection with Highly Active Antiretroviral Therapy: Effects on Virologic, Immunologic, and Toxicity Parameters

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples

A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance

A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V

Development of robust antiviral assays for profiling compounds against a panel of positive-strand RNA viruses using ATP/luminescence readout

Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance

Correlation between Viral Resistance to Zidovudine and Resistance at the Reverse Transcriptase Level for a Panel of Human Immunodeficiency Virus Type 1 Mutants

Interference between D30N and L90M in Selection and Development of Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1

Correlation of Phenotypic Zidovudine Resistance with Mutational Patterns in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1: Interpretation of Established Mutations and Characterization of New Polymorphisms at Codons 208, 211, and 214

Comparative Analysis of Two Commercial Phenotypic Assays for Drug Susceptibility Testing of Human Immunodeficiency Virus Type 1

Prevalence of Protease and Reverse Transcriptase Drug Resistance Mutations over Time in Drug-Naïve Human Immunodeficiency Virus Type 1-Positive Individuals in Rio de Janeiro, Brazil

High Degree of Interlaboratory Reproducibility of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Sequencing of Plasma Samples from Heavily Treated Patients

ANTIVIRAL ACTIVITY OF TENOFOVIR (PMPA) AGAINST NUCLEOSIDE-RESISTANT CLINICAL HIV SAMPLES

Testing Genotypic and Phenotypic Resistance in Human Immunodeficiency Virus Type 1 Isolates of Clade B and Other Clades from Children Failing Antiretroviral Therapy

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles

Patterns of Resistance and Cross-Resistance to Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors in Patients Treated with the Nonnucleoside Reverse Transcriptase Inhibitor Loviride

Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor

Suchergebnisse filtern